Glaukos Corporation announced that the US Centers for Medicare and Medicaid Services (CMS) has assigned a permanent ...
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, ...
The company said the move reduces administrative hurdles by facilitating easier claims processing for hospitals and clinics. ・Yartemlea is the first and only FDA-approved medicine for hematopoietic ...
Glaukos GKOS announced that its innovative keratoconus treatment, Epioxa (Epioxa HD / Epioxa), was assigned a permanent HCPCS ...
Pacira BioSciences (NASDAQ:PCRX) on Thursday announced that the U.S. Centers for Medicare and Medicaid Services (CMS) issued a product-specific J-code for its non-opioid pain therapy Exparel for ...
How a strong collaboration between clinical and billing teams can simplify J-code decoding, paving the way for improved patient access to innovative treatments. It’s an all-too-common story. A patient ...
The aflibercept 8 mg injection improves patient care by allowing longer intervals between treatments, explains Jose A. Martinez, MD, Austin Retina Associates. A new Healthcare Common Procedure Coding ...
Please provide your email address to receive an email when new articles are posted on . Ycanth has received a permanent J-code for the treatment of molluscum contagiosum. The code will be fully ...
WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent and ...